80 results about "Xenopus" patented technology

The invention provides a series of Galphaq protein variants that functionally couple to sensory cell receptors such as taste GPCRs (TRs) and olfactory GPCRs (ORs) in an overly promiscuous manner. According to the invention, the functional coupling can be determined, for example, by measuring changes in intracellular IP3, or calcium. In a particular embodiment, the Galphaq protein variants can be expressed in mammalian cell lines or Xenopus oocytes, and then evaluated using calcium fluorescence imaging and electrophysiological recording.

Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in Xenopus oocytes. Human and mouse homologs of the ferroportin1 gene have been identified. The invention includes isolated polynucleotides, vectors and host cells comprising nucleotide sequences encoding Ferroportin1 proteins and variants thereof, including those having iron transport function. The invention also includes polypeptides encoded by ferroportin1 genes and variants of such polypeptides, and fusion polypeptides comprising a Ferroportin1 or a portion thereof. Methods to produce a Ferroportin1, methods to produce antibodies to a Ferroportin1 and methods to identify agents binding to a Ferroportin1, which can be inhibitors or enhancers of Ferroportin1 iron transport activity, are also described. Inhibitors of Ferroportin1 activity can be used in a therapy for hemochromatosis.

The present invention relates to novel alternative forms of human acetylcholinesterase (AChE) and nucleotide sequences encoding the same. The genes encoding the novel forms of human AChE have been identified in various malignant tumor cells. In a further aspect, the invention relates to a transgenic animal assay system for evaluating efficacy of drugs against cholinergic proteins, prior to or in the course of therapeutic treatment. Transgenic animals, preferably developing tadpole of Xenopus or mice which express human AChE, are used. The transgenic animal assay system is also useful for evaluating the toxicity of substances which potentially block human AChE (e.g. organophosphorous compounds).

The invention provides an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide is designed and obtained through a rational moleculardesign method on the basis of family analogues Pexiganan of the antibacterial peptide magainin derived from the epithelium of xenopus laevis. The antibacterial peptide is an antibacterial peptide Pexi-1 with an amino acid sequence as shown in SEQ ID NO. 1 or an antibacterial peptide Pexi-2 with an amino acid sequence as shown in SEQ ID NO. 2. The antibacterial peptide provided by the invention hasgood structural characteristics, can significantly improve the antibacterial effect on staphylococcus aureus, salmonella and aspergillus flavus, effectively reduces the hemolysis rate and cytotoxicity of chicken erythrocytes, and can be effectively used in animal-related production activities.

The invention relates to a xenopus laevis feed. The feed comprises the following raw materials based on percentage composition of total material weight: 40-55% of fish meal, 8-12% of shrimp med, 0-10% of bran, 8-12% of wheat flour, 8-12% of peanut meal, 3-7% of saccharomyces cerevisiae and 0-25% of algae powder. The xenopus laevis feed provided by the invention is convenient to store, low in cost, balanced in nutrition, prepared according to the required nutrition of xenopus laevis in different growth stages of tadpole, froglet and adult frogs, and conductive to the healthy and fast growth and development of the xenopus laevis.

The invention relates to an artificial method for inducing natural spawning and incubation of xenopus laevis. The method comprises the following steps: selecting sexually mature female xenopus laevis which do not lay eggs within 3 months and sexually mature male xenopus laevis which do not discharge sperms within 3 months; subcutaneously injecting hormone in the female xenopus laevis and male xenopus laevis; placing the xenopus laevis into a spawning pond according to the method of two male and one female or three male and two female or four male and two female; and after the female xenopus laevis lay eggs, taking out the oosperms and placing the oosperms into an incubator to incubate, wherein the oosperms are changed into little tadpoles after incubating for 24 to 72 hours. The method promotes natural spawning of the xenopus laevis, is simple to operate, convenient to popularize, low in cost and low in technical difficulty, fills the gap of quick spawning of the xenopus laevis in China, can provide sufficient tadpoles for mass breeding, and is applicable to test in the scientific research institutions and commercial breeding of the xenopus laevis.

This invention relates to novel multi-substrate deoxyribonucleoside kinase variants. More specifically the invention provides novel deoxyribonucleoside kinase variants derived from insects or lower vertebrates, in particular from Drosophila melanogaster, from Bombyx mori, or from Xenopus laevis, novel polynucleotides encoding multi-substrate nucleoside kinase variants, vector constructs comprising the polynucleotide, host cells carrying the polynucleotide or vector, methods of sensitising cells to prodrugs, method of inhibiting pathogenic agents in warm-blooded animals, and pharmaceutical compositions comprising deoxyribonucleoside kinase variants of the invention.

The invention relates to a preparation method of a rrbp1 gene knock-out xenopus tropicalis model, and an application. The preparation method comprises the steps of selecting a rrbp1 gene knock-out target point, designing sgRNA, synthetizing a double-stranded DNA fragment, constructing a sgRNA expression vector, performing in vitro transcription to obtain the sgRNA, mixing the sgRNA with Cas9 proteins, performing microinjection into fertilized eggs, and performing screening so as to obtain the rrbp1 gene knock-out xenopus tropicalis model. According to the preparation method disclosed by the invention, a reliable genetic modification animal model is provided for clarifying the functions of a rrbp1 gene in xenopus tropicalis, and a powerful research tool is provided for further studying tumor and cardiovascular diseases related to the rrbp1 gene based on the model; and besides, the method disclosed by the invention provides technical support for innovation of xenopus tropicalis mode animal germplasm resources.

The invention belongs to the field of cells, and discloses a method for inducing fetal bovine fibroblast to reprogram. According to the invention, the fetal bovine fibroblast is subject to permeabilized treatment by a digitonin solution, and is subject to co-incubation with xenopus oocytes extract; whole medium containing 2mMcaCl2 is adopted to block reversible pores in the cell membrane, extract treated medium is adopted to cultivate and induce the fetal bovine fibroblast to reprogram to obtain fetal bovine fibroblast pluripotent stem cells. The method discloses by the invention is efficient, stable, and safe; the alkaline phosphatase staining of the fetal bovine fibroblast pluripotent stem cells disclosed by the invention shows a positive result; the acetylation degree of histone H3K9 is lowered; Oct-4 protein and pluripotent marker gene Oct-4, Nanog are expressed; therefore the fetal bovine fibroblast undergoes reprogramming, the gene expression mode of cells is changed to show characteristics of stem cell, partial growing totipotent is restored, and the fetal bovine fibroblast can be used as nuclear donor cells to prepare clone embryo for body cell clone.

The present invention concerns methods for de-differentiation and stabilize cells, such as progenitor cells, by introducing the cells into the cytoplasm of host oocytes, such as Xenopus laevis oocytes. Advantageously, this method obviates the need for any nuclear transfer procedure, which is known to disrupt the chromosomal architecture of donor and recipient cells. The present invention also concerns host oocytes encapsulating cells that have been introduced into their cytoplasm. The present invention also concerns cells that have been removed from the host oocytes.

The invention discloses the total length cloning of the cDNA of the new gene Xsynuclein of the GRK family of African laevis. The total length of the cDNA is 1040bp, which includes a complete and opening reading frame and can code the protein containing 129 amino acids. The invention also discloses two TR-PCR primers of the gene, TR-PCR method and technique of whole-mount in situ hybridization. The new gene Xsynuclein of the GRK family of African laevis has high level expression in the central nervous system in the period of embryo and adult. The new gene Xsynuclein can take part in the process of forming the forebrain of the embryo and has close relations to neurodegenerative diseases, breast cancer, ovarian cancer and the like. The new gene Xsynuclein of the GRK family of African laevis and the coding protein thereof will hopefully make breakthrough in curing neurodegenerative diseases, breast cancer, ovarian cancer and the like.

An isolated cDNA encoding a growth-inducing protein, Frzb, capable of stimulating bone, cartilage, muscle, and nerve tissue formation. Frzb binds to and modulates the activity of Wnt growth factors which play a role in various developmental and neoplastic processes. The cDNA and protein sequences of human, bovine and Xenopus Frzb are provided. Production and purification of recombinant Frzb are also described.

The invention relates to a cholic acid-XenGLP-1 (xenopus glucagon-like peptide-1) conjugated peptide and an application thereof. Side chains of XenGLP-1 are subjected to structural modification, a cholic acid micromolecular derivative with a high serum protein binding ratio is introduced, and the XenGLP-1 conjugated peptide with higher hypoglycemic activity and longer pharmacological action time is obtained. The XenGLP-1 conjugated peptide has significantly improved bioactivity and high long-term hypoglycemic and weight losing functions.

The invention discloses a xenopus laevis oocyte expression carrier with a yellow or red fluorescence protein label and application. pGH19 plasmid is modified through a molecular biology means, and isspecifically developed to be a carrier pGH19-EYFP or pGH19-mRFP which is suitable for expression of the xenopus laevis oocyte and contains the enhanced yellow or monomer red fluorescence protein label. The carrier can normally express the target gene, and can detect the distribution situation and the expression mode of the target protein with the yellow or red fluorescence label through a fluorescence microscope or a confocal microscope, and thus a more visual and simpler detection method can be provided for the protein situation of xenopus laevis oocyte expression. The spatiotemporal dynamicsof the protein expression can be observed in real time. The expression situation of the target protein can be detected only by using an universal antibody as for the following extraction, purification, identification and functional analysis of the target protein, the experimental process is greatly simplified, and the experimental time is saved and economic cost is reduced.

The invention discloses a method for screening uric acid-lowering small molecule compounds for promoting uric acid excretion based on a patch clamp technology. The method comprises the following stepsof: constructing recombinant plasmids for expressing a GLUT9 gene; instantaneously transfecting the recombinant plasmids to an HEK293T cell; after 18-24 hours, recording the change of a current whenthe GLUT9 cells are expressed to transport uric acid by utilizing a patch clamp technology; and verifying the reliability of the model through positive drugs, namely benzbromarone and probenecid, andnegative drugs, namely RDEA3170 and allopurinol. The method is simple, convenient and rapid to operate; the result is stable, reliable and good in reproducibility; compared with an existing method fordetecting isotope uptake by using xenopus oocytes, the method has the advantages that the consumed time is shorter, the cost is lower, and high-throughput screening of the GLUT9 inhibitor can be achieved.

The invention discloses a production application of mono-subunit RNA polymerase KP34RP in long-chain mRNA synthesis. The mono-subunit RNA polymerase is bacteriophago-like particle mono-subunit RNA polymerase (a formula is as shown in the description). The KP34RP is used for preparing long-chain cap-cas9mRNA which is as show in a sequence list SEQ ID NO.4, IRES-cas9mRNA which is as show in a sequence list SEQ ID NO.5, and IRES-sox7mRNA which is as show in a sequence list SEQ ID NO.6, wherein cas9 is extensively applied to gene editing, and sox7 plays an important role in embryonic development.While three types of mRNA transcription template plasmids are constructed, at the gene sequence 5'-terminal and 3'-terminal, sequence elements of a nucleoplasmin positioning signal sequence NLS derived from xenopus laevis which is as shown in a sequence list SEQ ID NO.1, an internal ribosome entry site sequence IRES from hepatitis C virus which is as shown in a sequence list SEQ ID NO.2 and poly(A)+BspQI which is as shown in a sequence list SEQ ID NO.3 are added. It is guaranteed that the in-vitro synthesized mRNA can be efficiently translated to a function protein with activity in a cell. Theproduction application is uniform in product, high in purity, reaches a milligram level in average, and is capable of completely meeting market requirements to mRNA research and application.

The present invention provides a method for quickly detecting thyroid interferent. It uses the tail of xanopus tadpole of 53-55 stage as test material, and uses thyroid hormone to induce it to be absorbed and shortened, at the same time it makes the testing method undergo the process of exposure treatment, and utilizes the comparison of difference of shortened condition of tail of testing material exposure group and contrast to evaluate the thyroid interference activity.